|
Day 1
|
|
Monday, 29 October, 2012
|
|
8:30 -
9:30
|
|
|
9:30 -
10:30
|
Ensuring the future sustainability of health systems in Latin America |
- Exploring the changing demographics of the region and their impact on the cost of delivering healthcare
- Focusing on the base of the pyramid – strategies to improve population health
- Ensuring growing access to healthcare by managing spiralling costs and keeping care affordable
- Managing growing longevity its impact on health costs
- Understanding the role of technology and innovation in improving productivity and reducing cost pressures within health systems
- Examining a range of global sustainable innovations
|
|
Hans Dohmann, MD
Municipal Secretary for Health
Rio de Janeiro, Brazil
|
|
Dr. Gonzalo Vecina Neto
CEO
Hospital Sirio-Libanes, Brazil
|
|
|
|
|
10:30 -
11:30
|
|
|
11:30 -
12:00
|
|
|
12:00 -
13:00
|
Using mobile and connected health care to transform through innovation |
- Understanding the opportunities that mHealth and telehealth present:
- To reduce the cost of care delivery in developed Western health systems
- To enable access to quality care in emerging health systems
- Assessing the scale of the savings available to health systems through the coordinated implementation of remote monitoring for chronic disease
- Leveraging the power of connected technologies to join up clinical professionals, enable care integration and deliver cost savings across health systems
-
Understanding global health reimbursement landscapes and their evolving approaches to connected health care
|
|
Amadeu Castro
Director
GSMA Brazil
|
|
|
|
|
13:00 -
14:30
|
|
|
14:30 -
15:30
|
|
|
15:30 -
16:00
|
|
|
16:00 -
17:00
|
Exploring the developing regional market for bio-similars and generic medicines |
- Exploring whether generic drug discovery presents a better opportunity to multi-national pharmaceutical companies than original drug discovery
- Developing the evidence required to prove where biosimilars are safely interchangeable with name-brand products
- Understanding the regulatory differences between novel and generic drug registration
|
|
Roberto Araujo
Clinical Research Director
RDO & Professor and Consultant
ICTQ, Brazil
|
|
|
|
|
17:00 -
18:00
|
|
